source
- AstraZeneca, Lilly and Bayer unveil new strategies at ESMO 2026 in MadridAt the European Society for Medical Oncology (ESMO) congress in Madrid, nearly 40,000 delegates gathered for the five-day meeting. AstraZeneca said it is evaluating the use of its immunotherapy Ke…
- Genmab reports phase 3 success for Elahere competitor and previews Merus buyout dataGenmab disclosed at the European Society for Medical Oncology meeting that its experimental therapy, positioned as a rival to Elahere, achieved a positive outcome in a phase 3 trial. The result si…